Breast cancer often relapses in distant organs even when complete regression of primary tumors is achieved after initial ...

We read with great interest the published results of the RADIOSA trial by Giulia Marvaso and colleagues.1 This well designed ...

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

Some of the most harmful genetic changes in cancer are also the hardest to see. These structural alterations, deep within a tumor's DNA, can fuel aggressive growth and evade standard testing ...

Cytoreductive surgery and advances in systemic therapy have improved the prognosis of primary advanced ovarian cancer and the therapeutic aim has shifted from a palliative situation to cure or at ...

Overall Best: HealthyLine Platinum Series PEMF Mat For those looking for a true powerhouse in PEMF therapy, the HealthyLine Platinum Series PEMF Mat stands out as the most versatile and ...

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also ...

The cancer institute needs to treat five patients before it can apply for accreditation. The goal is to do that within a year. As for Christine, we're told she's doing well.

Key Takeaways An anaphylactic reaction to Paraplatin necessitated a switch to Cytoxan, requiring patient advocacy for insurance approval. Pinch-off syndrome with the port-a-cath led to a replacement ...

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a ...

World-first "undruggable" cancer treatment enters human trial By Bronwyn Thompson June 13, 2025 Novel cancer drug PMR-116 will be put to the test in a world first trial in 2025 ...